

Title: Stroke Prevention in Atrial Fibrillation: Current Evidence for Tailoring Antithrombotic Therapy

Dates: November 23, 2015 – November 23, 2016

Locations:

<http://www.cmecorner.com/programs.asp?ProductID=1164&audience=Physicians>

Learning Objectives:

- Use evidence-based risk scoring assessments to properly risk stratify patients with atrial fibrillation, considering stroke and bleeding risks.
- Discuss key differences in the pharmacologic profiles of the new oral anticoagulants that may impact selection of a specific agent for an individual patient with atrial fibrillation.
- Select the correct dosage for oral anticoagulant therapy for patients with atrial fibrillation and renal impairment.
- Develop individualized guideline-based antithrombotic treatment regimens for stroke prevention in patients with atrial fibrillation.

Target Audience: This activity has been designed for cardiologists, hospitalists, internal medicine and primary care physicians, nurse practitioners, physician assistants, nurses, and other clinicians involved in the treatment of patients with AF.

Program Overview: Nonvalvular atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in clinical practice and afflicts more than 3 million people in the United States. AF is an independent risk factor for ischemic stroke severity, recurrence, and mortality. Individuals with AF have 4 to 5 times greater risk for ischemic stroke. The National Stroke Association emphasizes the importance of treatment to prevent stroke in patients with AF, noting that patients tend to experience worse outcomes from AF-related stroke compared with non-AF-related stroke. Poor outcomes associated with AF-related stroke include increased mortality, stroke recurrence, functional impairment, and dependency. Quality measures from multiple organizations attest to improvement needed in clinical practice to reduce death from stroke, which includes preventing stroke in patients with AF.

Faculty:

Andrew Krumerman, MD
Associate Professor of Clinical Medicine
Albert Einstein School of Medicine
Cardiology, Arrhythmia Service
Montefiore Medical Center



Bronx, NY

Physician Continuing Medical Education:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Clinical and Patient Educators Association (CPEA) and MCM Education. CPEA is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation Statement:

Clinical and Patient Educators Association designates this enduring activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest:

Clinical and Patient Educators Association (CPEA) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by CPEA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Commercial Support: This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

